Royalty Pharma Return on Tangible Equity 2019-2021 | RPRX
Current and historical return on tangible equity values for Royalty Pharma (RPRX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
|Royalty Pharma Return On Tangible Equity Historical Data
||TTM Net Income
||Return on Tangible Equity
||Finance - Miscellaneous Services
Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.